Amgen Reports Phase 3 FOURIER Results for Repatha in Cardiovascular Prevention

Amgen today announced results from the Phase 3 FOURIER trial evaluating Repatha (evolocumab) in patients with established cardiovascular disease on statin therapy. The trial met its primary endpoint, demonstrating a significant reduction in major adverse cardiovascular events with Repatha compared to placebo. The risk of cardiovascular death, myocardial infarction, or stroke was reduced by 20%.